"More Expensive Than a Worker's Salary": Price of Laboratory Monkeys in China Doubles in Five Years
Around 30 Million Won Per Monkey
Surge in Technology Transfers and New Drug Research
Supply Shortages Driving Prices Up
As new drug research surges in China, the price of a single laboratory monkey has reportedly soared to around 30 million won.
On the 18th (local time), the South China Morning Post (SCMP) in Hong Kong reported that "due to the surge in new drug research in China, the price of laboratory monkeys has risen to about 140,000 yuan (29.4 million won)."
Monkey. The photo is not related to any specific content in the article. Pixabay
View original imageAccording to the Chinese government's official procurement records, the price of laboratory monkeys, which are widely used at the preclinical stage to assess a drug's safety and its absorption, metabolism, and excretion in the body, has doubled over the past five years.
This phenomenon is analyzed as being driven by a sharp increase in technology transfer agreements between Chinese biotech companies and global pharmaceutical firms, and by a recovery in fundraising in the pharmaceutical sector, which together have pushed the number of new drug candidates entering early-stage trials to an all-time high.
Office workers at large Chinese companies earn 20 million won a year... 30 million won per monkey
According to a bid notice released earlier this month by the Shanghai Institute of Materia Medica, the budget allocated for 450 crab-eating macaques is 62 million yuan (13.02 billion won), or about 137,800 yuan (2.894 million won) per monkey.
SCMP reported that this exceeds the average annual salary of office workers at large Chinese companies. According to the latest data from China's National Bureau of Statistics, the average annual salary of employees at large companies with annual revenue of 20 million yuan (4.2 billion won) or more in 2024 was 102,452 yuan (2.152 million won).
Cui Cui, Head of Asia Healthcare Research at U.S. investment bank Jefferies, said, "As U.S. interest rate cuts have increased the capital available for biotech investment, more projects have moved into the early stages, and safety assessments have become necessary," adding, "This is leading to greater demand for monkeys."
She explained that the number of monkeys required varies depending on trial design and the type of candidate compound. For antibody-drug conjugate (ADC) candidates, about 70 to 100 monkeys per drug are needed in preclinical safety studies, whereas relatively simple drugs with lower toxicity risks require around 40 to 60 monkeys. She added that some small-molecule drugs can use dogs instead of monkeys.
Chinese pharmaceutical companies signed a record 157 technology transfer deals with global drugmakers last year, worth a total of 135.7 billion dollars. At the same time, there has been an increase in cases where loss-making new drug developers list on the Hong Kong stock exchange by using the Chapter 18A regime.
Helen Chen, Head of Biopharmaceuticals and Life Sciences in China at global strategy consulting firm L.E.K., analyzed that as clinical trials within China expand and Chinese companies increasingly prepare for and conduct overseas clinical trials, investigational new drug (IND) applications have increased, which in turn has boosted demand for toxicity studies that rely on non-human primates.
Supply-demand imbalance... prices likely to keep rising
The securities industry expects the supply-demand imbalance to persist for the time being. Founder Securities projected that annual supply of laboratory monkeys in China between 2025 and 2027 will be in the range of 49,000 to 52,400 animals, while annual demand will reach between 51,300 and 62,600.
On the supply side, it is not easy to expand production capacity in the short term, and some farms have already booked out their output through the first quarter of this year, according to the brokerage. It stated that, as a result, prices are likely to continue rising in the short term.
However, analysts believe it is unlikely that this sharp price increase will be passed on directly to patients. Cui said, "The most expensive stages in new drug research and development are Phase 1 to Phase 3 clinical trials, which take 5 to 10 years and cost millions of dollars," adding, "Higher safety assessment costs account for only a small share of total costs."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Tony Ren, Head of Asia Healthcare Research at Macquarie Capital, also explained that about 70% of new drug development costs are concentrated in late-stage clinical trials, so the cost of animal models does not significantly affect the overall cost.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.